ICT: Integrating Combined Therapies for Persons With Co-occurring Disorders

Sponsor
Stanford University (Other)
Overall Status
Completed
CT.gov ID
NCT02598518
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
38
1
2
30
1.3

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the effectiveness and implementability of ICT for co-occurring alcohol use and mental health disorders within community addiction treatment, as delivered by routine community addiction clinicians.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Integrating Combined Therapies
  • Behavioral: Standard Care
N/A

Detailed Description

The proposed study will evaluate the effectiveness and implementability of a manual-guided integrated psychosocial treatment, Integrating Combined Therapies (ICT). ICT is an adaptation of the Combined Behavioral Intervention (CBI) from NIAAA Project COMBINE, and expands CBI's indication for alcohol problems to extend to drug use and the most common psychiatric problems in addiction treatment. ICT is designed to be transferable to routine care settings and for delivery by the existing workforce. Findings from a 2014 study provide a signal for ICT effectiveness and implementation.

We intend to randomly assign 76 eligible patients in outpatient addiction treatment to ICT adapted standard care (ICT+SC) versus standard care only (SC). There are 2 specific aims for this study:

Aim 1: Relative to standard care alone, to evaluate if patients receiving ICT have more significant reductions in alcohol use and severity as measured by the 90-day Timeline Follow Back (TLFB), Addiction Severity Index (ASI), and Short Inventory of Problems (SIP).

Aim 2: Relative to standard care alone, to evaluate if patients receiving ICT have more significant reductions in psychiatric symptom severity, as measured by the Brief Symptom Inventory (BSI) adn the ASI psychiatric severity composite.

This study involves a two-group repeated measure design. This study is a randomized controlled trial. The investigators plan to examine the outcomes associated with ICT versus standard care among patients receiving outpatient addiction treatment services. The investigators will employ assessments at baseline, four-month follow-up, and seven-month follow-up. Eligible participants will be randomly assigned to ICT therapy (plus standard care) or standard care, and all will be followed for the research assessments regardless of whether they drop out of treatment early (whenever possible).

Patients admitted to the participating addiction treatment program are routinely screened for an alcohol use disorder using the AUDIT and a mental health disorder using the MMS. These forms are collected by clinic staff and scored for alcohol use disorder (AUDIT: 8 or greater) and mental health disorder (MMS: 6 or greater). Patients meeting the threshold criteria on the AUDIT and MMS measures are approached by clinic staff about potential interest in the study. If they wish to learn more about the study, the research assistant is contacted, a suitable time is arranged, and the patient engaged in the process of informed consent.

If consent is granted, the participant completes the baseline assessment. The baseline assessment consists of measures gathered via interview by a member of the research team, self-administered surveys completed directly by the participant, and review of the participant's medical record to extract substance use, treatment history, and chart diagnoses.

The interview portion of the assessment consists of :
  • Standardized interview designed to assess mental health diagnoses: Structured Clinical Interview for DSM5 (SCID).

  • A urine screen and breathalyzer to test for alcohol and other drugs.

  • Standardized follow-back method for gathering data on recent alcohol and drug use: Timeline Follow-back calendar (TLFB)

The self-administered portion of the assessment consists of measures designed to assess:
  • Alcohol and drug use, as well as associated problems in other life areas such as medical, employment, legal, social, and psychiatric: Addiction Severity Index

  • Psychiatric symptoms: Brief Symptom Inventory (BSI)

  • Mental health disorders: Modified MINI Screen (MMS)

  • Negative consequences of alcohol and substance use: Short Inventory of Problems- Alcohol and Drugs (SIP-AD)

  • Substance use symptoms and problems: Brief Addiction Monitor (BAM)

  • Treatment utilization: Recent Treatment Survey (RTS)

If the participant continues to meet criteria for a mental health disorder (i.e. SCID interview confirms diagnosis of DSM5 mental health disorder, he or she is randomized to receive the study ICT therapy or standard care (SC)

Research assessments are then also conducted at four months and seven months post baseline assessment. The follow-up assessments will consist of the same measures administered at baseline, with the exception of the SCID interview.

The investigators plan to randomize approximately 76 participants in the study.

Study Design

Study Type:
Interventional
Actual Enrollment :
38 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Integrating Combined Therapies for Persons With Co-occurring Disorders
Study Start Date :
Jul 1, 2015
Actual Primary Completion Date :
Sep 30, 2017
Actual Study Completion Date :
Dec 31, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Integrating Combined Therapies

Integrating Combined Therapies (ICT) is a 10-session, manual-guided individual therapy. ICT has three phases designed to address substance use, psychiatric problems and their interactions. MET is the first phase (2 sessions) and is focused on assessment, feedback and securing motivation to address problems and take steps. CBT is the second phase (5 sessions) and incorporates patient education and functional analysis, develops coping skills, teaches methods to challenge beliefs, and activates alternative behaviors. TSF (3 sessions) is focused on maintaining recovery and engaging in community-based recovery activities. Although ICT has core components, its application is flexible to accommodate the unique needs and problems of individual patients (and their comorbidities).

Behavioral: Integrating Combined Therapies
Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
Other Names:
  • ICT
  • Active Comparator: Standard Care

    Standard Care (SC) is the typical outpatient treatment that the patient would receive ordinarily at the identified addiction treatment program. SC service operates using the American Society of Addiction Medicine criteria (9 hours per week); group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.

    Behavioral: Standard Care
    Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
    Other Names:
  • SC
  • Outcome Measures

    Primary Outcome Measures

    1. Decrease from baseline in alcohol use (90-day Timeline Follow Back (TLFB) at 4-months and at 7-months [Baseline, 4-month, 7-month follow-up]

    2. Decrease from baseline in alcohol use severity (ASI; alcohol severity composite) at 4-months and at 7-months [Baseline, 4-month, 7-month follow-up]

    3. Decrease from baseline in alcohol use severity (Short Inventory of Problems (SIP)) at 4-months and at 7-months [Baseline, 4-month, 7-month follow-up]

    4. Decrease from baseline in psychiatric symptom severity (ASI; Psychiatric Severity Composite) at 4-months and at 7-months [Baseline, 4-month, 7-month follow-up]

    5. Decrease in psychiatric symptom severity (Brief Symptom Inventory (BSI)) at 4-months and 7-months [Baseline, 4-month, 7-month follow-up]

    Secondary Outcome Measures

    1. Decrease from baseline in drug use (90-day TLFB) at 4-months and at 7-months [Baseline, 4-month, 7-month follow-up]

    2. Decrease from baseline in positive toxicology screen (urine drug screen) at 4-months and at 7-months [Baseline, 4-month, 7-month follow-up]

    3. Decrease from baseline in drug use severity (ASI; Drug Severity Composite) at 4-months and 7-months [Baseline, 4-month, 7-month follow-up]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. At least 18 years old;

    2. Evaluated and admitted to outpatient addiction treatment services at RMHS Evergreen program and meets criteria for any alcohol or substance use disorder;

    3. Screened positive for an alcohol problem on the Alcohol Use Disorders Identification Test (AUDIT) (score of 8 or higher) (screening instrument);

    4. Screened positive for a mental health problem on the Modified MINI Screen (MMS) (score of 6 or higher) (screening instrument);

    5. Diagnoses confirmed by SCID (diagnostic interview); AND

    6. Willing and able to provide informed consent.

    Exclusion Criteria:
    1. They have acute psychotic symptoms and are not appropriately connected with mental health services;

    2. They have had a psychiatric hospitalization or suicide attempt within the past month (however, if the hospitalization or attempt was directly related to substance intoxication or detoxification and the person is currently stable, they are eligible); OR

    3. They have unstable medical or legal situations that would make participation for the full duration of the study highly unlikely.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Evergreen - Rutland Mental Health Rutland Vermont United States 05701

    Sponsors and Collaborators

    • Stanford University
    • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    Investigators

    • Principal Investigator: Mark P. McGovern, Ph.D., Stanford University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mark McGovern, Study Principal Investigator, Stanford University
    ClinicalTrials.gov Identifier:
    NCT02598518
    Other Study ID Numbers:
    • 1R21AA023001-01A1
    • 1R21AA023001-01A1
    First Posted:
    Nov 6, 2015
    Last Update Posted:
    Jun 29, 2018
    Last Verified:
    Jun 1, 2018
    Keywords provided by Mark McGovern, Study Principal Investigator, Stanford University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 29, 2018